Last reviewed · How we verify
NCT06206642
Comparing 18F-FAPI-04 and 18F-FDG PET/CT in Cancer Detection
NA trial testing PET/CT in Malignant Neoplasm in 92 participants. Completed in 31 December 2023.
31 October 2023
Quick facts
| Lead sponsor | Lanzhou University Second Hospital |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | crossover |
| Masking | single |
| Primary purpose | diagnostic |
| Enrollment | 92 |
| Start date | 1 April 2022 |
| Primary completion | 31 October 2023 |
| Estimated completion | 31 December 2023 |
| Sites | 1 location across China |
Drugs / interventions tested
- PET/CT
Conditions studied
- Malignant Neoplasm — all drugs for Malignant Neoplasm →
Sponsor
Lanzhou University Second Hospital
Who can join
Adults 18 to 90, any sex, with Malignant Neoplasm. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Evaluating fluoro-18-fibroblast activation protein inhibitor-04 positron emission computed tomography's diagnostic efficacy for primary malignancies versus 18F-2-fluoro-2-deoxy-D-glucose fluorodeoxyglucose.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06206642
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of PET/CT
Trials testing the same drug.
- NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
- NCT07523997 — Imaging of Endometriosis With Total-body PET-CT (PET-Endo) · not yet recruiting
- NCT06914427 — PET/CT Imaging Study With Simultaneous Dual-nuclide Imaging Technique · NA · not yet recruiting
- NCT06636175 — 64Cu-LLP2A for Imaging Hematologic Malignancies · EARLY_PHASE1 · recruiting
- NCT06479187 — PSMAtrack-tracking Changes in PSMA-PET During Initial Therapy for Metastatic Hormone-sensitive Prostate Cancer · Phase 4 · active not recruiting
Other recruiting trials for Malignant Neoplasm
Currently open trials in the same condition.
- NCT07302347 — A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participan · Phase 1, PHASE2 · recruiting
- NCT07487883 — Cadherin 3(CDH3)-Targeted PET in Lung Malignant Tumors · recruiting
- NCT07252739 — KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) · Phase 2 · recruiting
- NCT07247110 — A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001) · Phase 1 · recruiting
- NCT07131007 — Construction and Evaluation of Tumor Immunotherapy and Organ Damage Early Warning System Based on Multi-omics · recruiting
Other Lanzhou University Second Hospital trials
Trials by the same sponsor.
- NCT07492147 — Effect of Negative Pressure Suction on Fluid Absorption and Infection in Flexible Ureteroscopy · recruiting
- NCT06945432 — Comparing 68Ga-CTR-FAPI and 18F-FDG PET/ CT in Cancer Detection · completed
- NCT06657755 — Evaluation of ENPP1 Expression and Immune Response in Bladder Cancer Patients · completed
- NCT07299253 — Preclinical Safety Evaluation and First-in-Human Translational Study of [177Lu]Lu-TEFAPI-06 · EARLY_PHASE1 · completed
- NCT06600399 — Correlation Between Prostate-specific Membrane Antigen Positron Emission Tomography and Arterial Spin Labeling Perfusion · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06206642 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Lanzhou University Second Hospital
- Last refreshed: 16 January 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06206642.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing